{"id":"NCT00716859","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","officialTitle":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2008-07-16","resultsPosted":"2010-12-02","lastUpdate":"2021-02-03"},"enrollment":139,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma"],"interventions":[{"type":"DRUG","name":"Timolol","otherNames":[]},{"type":"DRUG","name":"latanoprost","otherNames":[]}],"arms":[{"label":"Timolol","type":"ACTIVE_COMPARATOR"},{"label":"latanoprost","type":"EXPERIMENTAL"}],"summary":"To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.","primaryOutcome":{"measure":"Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Timolol","deltaMin":5.72,"sd":0.81},{"arm":"Latanoprost","deltaMin":7.18,"sd":0.81}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"36 Weeks","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":48,"countries":["United States","Belgium","Colombia","Czechia","France","Germany","India","Italy","Philippines","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Slovenia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6111137&StudyName=A%20Phase%203%20Prospective%2C%20Randomized%2C%20Double-Masked%2C%2012-Week%2C%20Parallel%20Group%20Study%20In%20Pediatric%20Subjects%20With%20Glaucoma."]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":69},"commonTop":["Nasopharyngitis","Headache","Conjunctival hyperaemia, study eye","Conjunctival hyperaemia, both eyes","Pyrexia"]}}